J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Biogen (BIIB) on February 19 and set a price target of $269.00. The company’s shares closed last Wednesday at $284.21.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 21.0% and a 54.5% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $311.67, which is an 11.8% upside from current levels. In a report issued on February 5, DZ BANK AG also downgraded the stock to Hold with a $264.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $363.92 and a one-year low of $223.25. Currently, Biogen has an average volume of 1.3M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Read More on BIIB: